Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276421 | 0.80 | — | — | |
| SCHEMBL4273428 | 0.75 | SIGMAR1 (0.38) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4264728 | 0.75 | NPC1 (0.40) | KDM4ELMNACYP1A2POLBBLM | |
| SCHEMBL4276559 | 0.73 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4271539 | 0.72 | CHRM1 (0.32) | — | |
| SCHEMBL4274377 | 0.72 | ACVR1 (0.40) | LMNACYP1A2POLBBLMHIF1A | |
| SCHEMBL2004902 | 0.71 | KDM4E (0.46) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4265742 | 0.71 | ALPL (0.44) | CYP1A2PTGS2GABRG2GABRB3GABRA5 | |
| SCHEMBL4276909 | 0.69 | GABRA1 (0.38) | POLBGABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL4276452 | 0.66 | CYP17A1 (0.33) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605183-B2 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2009-10-20 | — | — | US | disclosed |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | KOYAMA SHOZO | 2008-08-21 | — | — | US | disclosed |
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2007-03-22 | — | — | US | disclosed |
| EP-0780122-B1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | KOYAMA SHOZO (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6710090-B2 | A CYCLOHEX-1-EN-2-ONE COMPOUND | KOYAMA SHOZO (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6346551-B1 | ANTIBACTERIAL, ANTIFUNGAL, ANTIVIRAL, BACTERICIDAL AND/OR STERILIZATION AGENTS, ANTICANCER DRUGS, BLOOD COAGULATION AND FIBRINOLYSIS INHIBITORS AND/OR BLOCKING AGENTS, INHIBITORY AND/OR BLOCKING AGENTS OF ANTIGEN-ANTIBODY REACTIONS | KOYAMA SHOZO (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0780122-A1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | Koyama, Shozo (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, SERPINB6, CD74 | KDM4E 3382/4885LMNA 4388/4885CCR1 889/4885 |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD69, TFPI, SERPINE1 | KDM4E 3869/4885LMNA 997/4885CCR1 2483/4885 |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, MCL1, CD74 | KDM4E 3887/4885LMNA 4495/4885CCR1 754/4885 |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | CD47, MCL1, BAK1 | KDM4E 3452/4885LMNA 4359/4885CCR1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.